The Technical Analyst
Aerie Pharmaceuticals, [AERI]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Aerie Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $15.25
/ 18 nov 2022 @ 16:00
| RATING 2022-11-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 15.17 - 15.33 ( +/- 0.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-11-21 | Mchugh Julie | Sell | 16 854 | Stock Option (right to buy) |
| 2022-11-21 | Mcgraw Benjamin F Iii | Sell | 16 854 | Stock Option (right to buy) |
| 2022-11-21 | Mcdonnell Peter J | Sell | 16 854 | Stock Option (right to buy) |
| 2022-11-21 | Kopczynski Casey C. | Sell | 65 941 | Stock Option (right to buy) |
| 2022-11-21 | Lang Peter Frederick | Sell | 160 551 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -84.86 |
| Last 98 transactions |
| Buy: 1 757 162 | Sell: 988 060 |
Forecast:
01:40 - $17.50
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.25 (0.00% ) |
| Volume | 1.215 mill |
| Avg. Vol. | 0.787 mill |
| % of Avg. Vol | 154.44 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AERI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AERI
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Latest Press Releases
2022-11-22 01:01:00 - Press Release
Alcon Completes Acquisition Of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
Geneva--( business wire )--alcon (six/nyse: alc), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of aerie pharmaceuticals, inc. (nasdaq: aeri, “aerie”). this transaction helps bolster alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pipeline.
2022-11-03 16:01:00 - Press Release
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
Durham, n.c.
2022-10-14 18:18:00 - Press Release
Aerie Pharmaceuticals - Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Aerie Pharmaceuticals, Inc. - Aeri
New orleans--(business wire)--former attorney general of louisiana charles c.
2022-09-28 01:14:00 - Press Release
Shareholder Investigation: Halper Sadeh Llc Investigates Aeri, Ecom, Pfs, Lbai
New york , sept. 28, 2022 /prnewswire/ -- halper sadeh llc, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: aerie pharmaceuticals, inc. (nasdaq: aeri)'s sale to alcon for $15.25 per share.
2022-09-13 08:00:00 - Press Release
Aerie Pharmaceuticals To Host Key Opinion Leader Event On Dry Eye Disease: Current Landscape, Unmet Needs, And Emerging Treatment Options
Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a key opinion leader (kol) webinar on friday, september 23, 2022 from 10:00 a.m. – 11:30 a.m. eastern time. the event will feature dr. laura periman, md, of the periman eye institute, and dr. john sheppard, md, of the virginia eye consultants, who will discuss new
Latest News
2022-11-03 19:36:07 - Zacks Investment Research
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-21 10:33:38 - Zacks Investment Research
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
Here are four top-ranked liquid stocks, Oxford Industries (OXM), Aerie Pharmaceuticals (AERI), Perion Network (PERI), and Pure Storage (PSTG), which investors can add to their portfolio for returns.
2022-10-21 09:47:16 - Zacks Investment Research
5 Small Hidden Gems Flying High Despite Market's Bloodbath
We have narrowed our search to five small cap stocks that have provided more than 35% returns year to date,These are: AERI, AMAL, RELL, PHX and SBOW.
2022-10-20 12:02:20 - Zacks Investment Research
5 Stocks to Bet on in an Innovation-Driven Drug Industry
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
2022-10-17 11:17:59 - Zacks Investment Research
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.
2022-09-29 11:17:39 - Zacks Investment Research
Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?
Here is how Aerie Pharmaceuticals (AERI) and Hanger (HNGR) have performed compared to their sector so far this year.
2022-09-12 11:17:19 - Zacks Investment Research
Is Aerie Pharmaceuticals (AERI) Outperforming Other Medical Stocks This Year?
Here is how Aerie Pharmaceuticals (AERI) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
2022-08-26 11:18:47 - Zacks Investment Research
Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?
Here is how Aerie Pharmaceuticals (AERI) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
2022-08-26 09:03:57 - The Motley Fool
Why Aerie Pharmaceuticals Was Soaring So High This Week
You'd vault skyward, too, if a big-pocketed company were willing to spend a lot of coin on acquiring you.
2022-08-24 16:02:50 - GuruFocus
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.